Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 7/20 | 0.42 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL339817 | 0.98 | LPAR3 (0.44) | LPAR3LPAR2GPR84TRPM8PLA2G2D | |
| SCHEMBL339431 | 0.93 | GPR84 (0.39) | LPAR3LPAR2GPR84TRPM8 | |
| SCHEMBL339643 | 0.85 | FOLH1 (0.35) | GPR84 | |
| SCHEMBL338061 | 0.81 | LPAR3 (0.48) | LPAR3LPAR2GPR84TRPM8 | |
| SCHEMBL339802 | 0.80 | PPARD (0.35) | — | |
| SCHEMBL340078 | 0.79 | TRPM8 (0.46) | LPAR3LPAR2GPR84TRPM8 | |
| SCHEMBL16163129 | 0.77 | LPAR3 (0.48) | LPAR3LPAR2TRPM8PLA2G2D | |
| SCHEMBL11112376 | 0.77 | GPR84 (0.58) | GPR84 | |
| SCHEMBL3797655 | 0.76 | LPAR3 (0.56) | LPAR3LPAR2 | |
| SCHEMBL11434237 | 0.76 | LPAR3 (0.56) | LPAR3LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097753-B2 | Mixtures composed or monocarboxy-functionalized dialkylphosphinic acids, their use and a process for their preparation | CLARIANT FINANCE (BVI) LIMITED (VG) | 2012-01-17 | — | — | US | disclosed |
| EP-1832594-B1 | Compounds of mono-carboxyl functionalised dialkylphosphine acid salts, a method for their manufacture and their application | CLARIANT FINANCE BVI LTD (VG) | 2011-05-18 | — | — | EP | disclosed |
| US-20070213436-A1 | Mixtures composed or monocarboxy-functionalized dialkylphosphinic acids, their use and a process for their preparation | CLARIANT INTERNATIONAL LTD | 2007-09-13 | — | — | US | disclosed |
| EP-1832594-A1 | Compounds of mono-carboxyl functionalised dialkylphosphine acid salts, a method for their manufacture and their application | CLARIANT INTERNATIONAL LTD. (CH) | 2007-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213436-A1 | Mixtures composed or monocarboxy-functionalized dialkylphosphinic acids, their use and a process for their preparation | PAH, ALKBH3, FTO | LPAR3 640/4885LPAR2 843/4885GPR84 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.